Dual Bispecific Regimen Shows Early Prostate Cancer Activity

Company Johnson & Johnson Event Type Phase 1 data (SITC late-breaking) Modality T-cell engager plus costimulatory bispecific Asset Pasritamig plus JNJ-9401 Target KLK2×CD3; PSMA×CD28 Disease Area Metastatic castration-resistant prostate cancer Summary Recovered source-gap item: Johnson & Johnson disclosed November 9 Phase 1 activity for pasritamig…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *